Octapharma Advancing Human Lives...
It’s In Our Blood
We Are Octapharma— Focused
on Patient Care
We are the largest privately owned human protein products manufacturer in the world
■ We develop and manufacture high-quality human protein products from human plasma and human cell lines
■ We are dedicated to improving the quality of life of patients suffering from a variety of blood clotting disorders, immune deficiencies, and other illnesses
■ The “octa” in our name is derived from the Greek word for 8, the factor deficient in people with hemophilia A
As a private, family-owned company, we believe in investing to make a difference in people’s lives— and have been doing so for nearly 40 years.
Our mission is to ensure the safe and optimal use of human proteins
Octapharma was founded in 1983 by Wolfgang Marguerre on the fundamental principle of improving the safety and lives of patients around the world by:
■ Working closely with scientific communities and patient associations around the world, we are able to develop a deeper appreciation of their needs and challenges
■ Leveraging this knowledge to further innovate and improve our products and the overall patient experience
Our passion drives us to provide new health solutions that advance human life by:
■ Investing in responsible governance
■ Investing in solid relationships with patientcentered organizations
■ Investing in research and development
An Independent, Private Company With a High Degree of Flexibility and Responsibility
Octapharma focuses exclusively on human protein products
The Octapharma mission, for the safe and optimal use of human proteins, conveys our focus and dedication to a specialized portfolio of products. These products, derived from human plasma and human proteins, are categorized into 3 therapeutic areas:
■ Hematology (coagulation/bleeding disorders)
■ Immunotherapy (immune-mediated diseases and deficiencies)
■ Critical Care (intensive care and emergency medicine)
Octapharma currently offers 7 different human protein products in the US, with several more in our product development pipeline.
Octapharma employs over 9,300 people worldwide—supporting patients in 118 countries
Our global headquarters is located in Lachen, Switzerland and our American headquarters is located in Paramus, New Jersey. Octapharma owns 6 state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.
“Octapharma was founded on the principle of enhancing patient safety. Being privately owned allows us to preserve our fundamental principles without compromise.”
Wolfgang Marguerre, Founder and Chairman
The First Company to Apply Solvent-Detergent Virus
Inactivation to FVIII Production
“Responsibility is not something you get, it is something you take.”
Wolfgang Marguerre
Octapharma has pioneered a number of safety innovations that have set the standard for the protein products industry, providing a sense of confidence to patients and healthcare professionals alike
■ Our founder, Wolfgang Marguerre, partnered with the NY Blood Center in 1984 to develop the breakthrough solvent/detergent (S/D) process for virus inactivation
■ Octapharma’s inaugural product was the first antihemophilic factor to use the innovative S/D technology
■ Octapharma was the first company to launch high-purity, virus-activated Factor VIII and Factor IX concentrates; the first company to launch a liquid immunoglobulin preparation; and the first company to launch virusinactivated plasma for transfusion
■ Today, the World Federation of Hemophilia (WFH) recognizes S/D virus inactivation as the gold standard for safety from highly infectious enveloped viruses, and recommends that the S/D process be considered as the option of choice
Empowering Patients to Go Further in Their Life Journey
Since 2009, Octapharma has been a leading corporate sponsor of Save One Life
■ Save One Life is a global, non-profit organization that provides direct support to children and adults in developing countries who are living with bleeding disorders
■ Octapharma’s founder and chairman, Wolfgang Marguerre, personally sponsors over 100 beneficiaries enrolled in the Save One Life program
Helping patients reach new heights
■ Octapharma was proud to sponsor Save One Life board member and mountaineer Chris Bombardier, who made history as the first person with severe hemophilia to summit Mount Everest
■ Chris’s journey was documented in Bombardier Blood, an inspirational film made possible by Octapharma
“As I pursued my dream of climbing Mt. Everest, I needed to find a sponsor that saw the vision and was willing to take the risk. Octapharma was the perfect match and a gracious sponsor. Their support not only allowed me to achieve a dream of a lifetime, but also allowed this journey to be captured and shared with the world. Octapharma’s commitment to inspiring the community and effecting positive change has been incredible!”
Chris Bombardier
Every Unit Is a Life
Each year, Octapharma helps thousands of patients with life saving therapies
“Octapharma is committed to providing patients with life-enhancing and life-saving therapies. Helping patients with chronic diseases maximize their quality of life is central to Octapharma’s mission and culture.”
Flemming Nielsen President, Octapharma
USA
Continuing education and scientific support
■ Octapharma supports a number of global and regional scientific congresses in collaboration with healthcare professionals, including the WFH, European Association of Hemophilia Disorders, and the International Patient Organization for Primary Immunodeficiency
“The Heidelberg facility is in my hometown, only a few minutes from my birthplace and the school I attended as a boy. I feel very proud that we are focusing these key research activities in this excellent university city. The groundbreaking work being carried out here will have international reach.”
Wolfgang Marguerre
■ Octapharma also oversees national and international programs that support disease diagnosis and treatment pathways
Investing in research
Our $25 million Heidelberg research facility is dedicated to human recombinant technology and recombinant protein drug development.
How to Contact Octapharma
Octapharma USA, Inc. 117 W. Century Road
Paramus, NJ 07652
Tel: 201-604-1130
www.octapharmausa.com
Customer Service: uscustomerservice@octapharma.com
Medical Affairs: usmedicalaffairs@octapharma.com
Reimbursement: usreimbursement@octapharma.com
For all inquiries relating to drug safety, or to report adverse events please contact our Local Drug Safety Officer:
Tel: 201-604-1137
Cell: 201-772-4546
Fax: 201-604-1141
or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Octapharma at a glance…
■ Founded by Wolfgang Marguerre in 1983
■ The largest privately-owned human protein products manufacturer in the world
■ Independent, flexible, patient-care focused
■ Pioneered the solvent/detergent (S/D) viral inactivation process
■ Focused on the development and manufacture of high-quality human proteins from human plasma and human cell lines
■ 7 R&D sites, 6 state-of-the-art manufacturing facilities, and more than 120 plasma centers
– More than 9,300 employees around the world, including over 4,000 in the US
– 7 human protein products currently available in the US
– Ongoing investment in research and new product development
USA, Inc.
117 W. Century Road Paramus, NJ 07652
©2020. Octapharma USA, Inc. All rights reserved. Date of preparation: 4/2020. OCTA-0218-COT
Octapharma